
First Patient Enrolled in Stoke Therapeutics’ Phase 1 Study of STK-002 for ADOA
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicinefor the Treatment of Autosomal Dominant Optic Atrophy (ADOA) Stoke Therapeutics, Inc. a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential…











